• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Blogs » BioWorld MedTech Perspectives » Cutting the fat, without actually cutting

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Cardiovascular

Cutting the fat, without actually cutting

Nov. 15, 2013
By Amanda Pedersen

Cheesburger and StethoscopeAmerica is the fattest country in the world. The obesity epidemic is one of the largest problems facing the healthcare system, both from a clinical and an economic perspective. Pardon the pun.

The Centers for Disease Control and Prevention reports that more than one-third of U.S. adults (35.7%) are obese. Because obesity is associated with so many other health problems, such as heart disease and diabetes, the topic has drawn a great deal of attention at industry gatherings, including the Cleveland Clinic Medical Innovation Summit last month where the clinical focus was on obesity, diabetes, and the metabolic crisis.

But recognizing that obesity is a problem is only half the battle. Finding a solution to this problem, which affects both children and adults and creates an overwhelming drain on healthcare resources, seems to be easier said than done.

“We just need one winner,” Philip Schauer, MD, the director of Bariatric & Metabolic Institute at the Cleveland Clinic, told me at a networking event during the Medical Innovation Summit.

The bariatric device space came close to declaring a winner a few years ago with a technology that is no longer in development. Satiety (Palo Alto, California) had developed the Trans-oral Gastroplasty, or TOGA, procedure. That procedure involved the creation of a gastric sleeve so small that when even little amounts of food entered and pushed against its wall, the patient felt a sensation of fullness. Satiety got as far as completing a pre-market approval study in the U.S. and the TOGA procedure even landed on the Cleveland Clinic’s prestigious Top 10 list of innovations expected to make a big impact on healthcare in 2011. But when less-than stellar weight loss results came in, the company was shut down.

All hope is not lost, however. I recently wrote about ReShape Medical (San Clemente, California), a company trying to bring a non-surgical weight-loss device to the U.S. market. ReShape reported earlier this month that its REDUCE trial for its ReShape Duo Intragastric Balloon met its primary efficacy endpoints. That makes ReShape the first company to meet its primary efficacy endpoints in a U.S. randomized, sham-controlled pivotal trial for weight loss.

ReShape plans to submit a pre-market approval application to the FDA in the second quarter of 2014. Richard Thompson, president/CEO of ReShape Medical, told me there was significant interest in participation in the study, which speaks to the clear need for a product like the ReShape Duo balloon. The balloon is endoscopically placed down the esophagus and into the stomach without requiring any incisions, sutures or fixation to the body. Once in place, the balloon is inflated with saline and designed to take up much of the stomach’s volume, causing patients to eat smaller portions and to feel full sooner. The device does not change or alter the patient’s anatomy, and is fully reversible. The balloon is removed after six months.

What I think is interesting about this procedure, aside from the incision-free aspect, is the fact that the device is intended to help patients achieve a healthy weight, but the patients are still expected to work with dietitians, doctors and nurses to learn healthy diet and exercise habits during and beyond the treatment period. The device could go a long way towards bridging a very large gap of patients who are eligible for bariatric surgery but refuse to consider that as an option.

Interestingly, Thompson pointed out that fear of surgery is only part of the reason so many patients decline the surgical weight loss option. Many patients simply want to feel like they are solving the problem on their own, rather than feel like they are giving up by having surgery. For those patients, ReShape could be the help they are looking for without any stigmas they might have regarding surgery.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 22, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe